Regeneron Pharmaceuticals REGN Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $727.2M-13.9% | $844.6M-42.2% | $1.46B+4.9% | $1.39B+72.1% | $808.7M-11.9% | ||
| $123.2M-15.0% | $145M+6.1% | $136.7M+1.2% | $135.1M+6.5% | $126.9M+0.4% | ||
| $257.4M+3.2% | $249.3M+5.2% | $237M-5.8% | $251.7M-1.6% | $255.7M-16.0% | ||
| -$1.2M— | —— | —— | —— | -$657.8M-658% | ||
| -$26.6M— | $0-100% | $82.6M+94.4% | $42.5M-72.1% | $152.3M+29.4% | ||
| $107.7M— | $0-100% | $759.2M+251% | $216.4M+201% | -$214.1M-195% | ||
| $99.6M+3,313% | -$3.1M— | —— | -$142.9M-907% | $17.7M— | ||
| $1.08B-7.8% | $1.17B-27.7% | $1.62B+41.4% | $1.14B+9.5% | $1.05B-17.2% | ||
| $230.6M-7.3% | $248.7M+23.5% | $201.4M-8.0% | $219M-4.5% | $229.3M+14.9% | ||
| -$428.9M— | —— | -$402.9M+63.2% | -$1.09B-269% | $647.5M— | ||
| $97.8M+5.5% | $92.7M+1.6% | $91.2M-1.5% | $92.6M-1.3% | $93.8M— | ||
| $794.3M+18.3% | $671.7M+1.2% | $664M-37.4% | $1.06B+1.9% | $1.04B+7.0% | ||
| $163.1M-67.6% | $503.5M+1,149% | $40.3M+27.9% | $31.5M-48.0% | $60.6M-33.3% | ||
| $73.2M-85.9% | $519.2M+17,207% | $3M-46.4% | $5.6M+30.2% | $4.3M-98.3% | ||
| -$802.2M-2.8% | -$780.1M-8.7% | -$717.9M+36.4% | -$1.13B-3.6% | -$1.09B+4.1% | ||
| -$900K— | —— | —— | $400K-33.3% | $600K+186% | ||
| -$153.1M-125% | $610.6M+22.7% | $497.5M+146% | -$1.08B-278% | $604M— | ||
| —— | $10.4M0.0% | $10.4M0.0% | $10.4M0.0% | $10.4M-20.9% | ||
| $96M-58.7% | $232.5M-16.5% | $278.6M+106% | $135.2M-2.8% | $139.1M-50.4% | ||
| $198.6M— | —— | $47.9M-79.2% | $230.7M+28.5% | $179.5M+225% | ||
| -$55.6M+59.4% | -$136.9M-740% | -$16.3M-178% | $20.9M+753% | -$3.2M+95.3% | ||
| $48.9M+16.4% | $42M-3.0% | $43.3M-76.9% | $187.8M+345% | $42.2M-37.4% | ||
| $0— | —— | —— | —— | -$10.3M— | ||
| $848.3M-8.0% | $922M-34.9% | $1.42B+53.2% | $925.4M+13.4% | $815.8M-23.3% | ||
| $848.3M-8.0% | $922M-34.9% | $1.42B+53.2% | $925.4M+13.4% | $815.8M-23.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Regeneron Pharmaceuticals generate?
- Regeneron Pharmaceuticals (REGN) generated $5.0B in operating cash flow over the trailing twelve months.
- What is Regeneron Pharmaceuticals's free cash flow?
- After $899.7M of capital expenditures, Regeneron Pharmaceuticals's free cash flow was $4.1B over the trailing twelve months, up 32.6% year over year.
- Where does Regeneron Pharmaceuticals's cash flow data come from?
- Every line is extracted from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
